Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo

Journal of Experimental Medicine

Volumn 192, Issue 11, 2000, Pages 1637-1643

  Yee, Cassian ^a,e   Thompson, John A ^a   Roche, Patrick ^c   Byrd, David R ^b   Lee, Peter P ^d   Piepkorn, Michael ^a   Kenyon, Karla ^a   Davis, Mark M ^d   Riddell, Stanley R ^a   Greenberg, Philip D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d STANFORD UNIVERSITY   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Autoimmunity; Immunotherapy; Melanoma; T lymphocytes; Vitiligo

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 100; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN;

ADULT; ARTICLE; CASE REPORT; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; VITILIGO;

ANTIGENS, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOCYTES; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VITILIGO;

EID: 0034606276     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.192.11.1637     Document Type: Article

References (24)

1. Prognostic significance of hypopigmentation in malignant melanoma
2. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
3. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro
4. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
5. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
6. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
7. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
8. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
9. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells
10. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
11. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene
12. + HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant
13. Phenotypic analysis of antigen-specific T lymphocytes
14. + T-cell responses
15. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
16. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
17. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma
18. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
19. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
20. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
21. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells
22. A new look at T cells
23. Management of IL-2 toxicity
24. Eye-derived cytokines and the immunosuppressive intraocular microenvironment: A review